Abstracts tagged "biologic drugs and spondylarthritis"

Abstract Number: 1663 • 2018 ACR/ARHP Annual Meeting
Correlation between Biologics and Bath Ankylosing Spondylitis Metrology Index within the First 12 Months of Treatment in Patients with Axial Spondyloarthritis
Clare Longton¹, Marco Massarotti² and Marwan Bukhari³, ¹Rheumatology, Royal Lancaster Infirmary, University Hospitals of Morecambe Bay NHS Foundation Trust, Lancaster, United Kingdom, ²Rheumatology, Royal Lancaster Infirmary, University Hospital of Morecambe Bay NHS Foundation Trust, Lancaster, United Kingdom, ³Royal Lancaster Infirmary, Lancaster, United Kingdom
Background/Purpose: Several studies demonstrate efficacy of biologics on disease activity measured by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in patients with axial spondyloarthritides…
Abstract Number: 1533 • 2017 ACR/ARHP Annual Meeting
Efficacy of Switching Biological Dmards in Patients with Axial Spondyloarthritis: Results from a Systematic Literature Review
Victoria Navarro-Compán¹, Chamaida Plasencia-Rodriguez², Eugenio De Miguel³, Petra Diaz del Campo⁴, Alejandro Balsa³ and Jordi Gratacos-Masmitja⁵, ¹Rheumatology, Hospital Universitario La Paz, Madrid, Spain, ²University Hospital La Paz, IdiPaz, Madrid, Spain, ³Rheumatology, University Hospital La Paz, IdiPaz, Madrid, Spain, ⁴Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ⁵Rheumatology, Parc Tauli Hospital Universitari, Sabadell, Barcelona, Spain
Background/Purpose: Approximately 30-50% of patients with axial SpA (axSpA) who receive a first bDMARD do not respond well. Current practice in these patients is switching…
Abstract Number: 2147 • 2015 ACR/ARHP Annual Meeting
The Effect of Sulfasalazine and Methotrexate on the Immunogenicity of Infliximab and Adalimumab in Patients with Spondyloarthritis
Ana Martínez¹, Chamaida Plasencia-Rodriguez², Dora Pascual-Salcedo³, Eva L. Kneepkens⁴, Gertjan Wolbink⁵, Alejandro Villalba⁶, Teresa Jurado¹, Diana Peiteado⁶, Laura Nuño⁶, Andrea Jochems¹ and Alejandro Balsa⁶, ¹Immunology Unit, La Paz University Hospital-IdiPaz, MADRID, Spain, ²Rheumatology Department, La Paz University Hospital-Rheumatology Department, Madrid, Spain, ³Immunology Unit, La Paz University Hospital-Immunology, Madrid, Spain, ⁴Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁵Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁶Rheumatology, La Paz University Hospital-Rheumatology Department, Madrid, Spain
Background/Purpose: Classic DMARDs are not routinely prescribed for axial spondyloarthritis (SpA). Recent studies have found that concomitant therapy with methotrexate (MTX) reduced immunogenicity of TNF…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].